Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyMedical Mutual - Ohio Vitamin D Coverage Update | …
    Ask Trek AI about this page
    Modifiedmedical mutual - ohioPolicy AHS - G2005

    Vitamin D Testing

    Customize your policy alerts

    Sign up for medical mutual - ohio Policy AHS - G2005 alerts

    Get alerted when Policy AHS - G2005 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and clinical criteria for serum vitamin D testing (25-hydroxyvitamin D and 1,25-dihydroxyvitamin D), including D2/D3 fraction testing, for Medical Mutual - Ohio members.

    Policy Summary
    Payermedical mutual - ohio
    PolicyVitamin D Testing
    Policy CodePolicy AHS - G2005
    Change TypeCoverage criteria revisedmaterial changes
    Effective DateJun 1, 2026
    Last ReviewDec 3, 2025
    Next Review DateDec 3, 2025
    Key ActionWhen ordering 25-hydroxyvitamin D, document a qualifying clinical indication and limit testing to no more than one test every six months for covered indications.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Combined CC1 and CC3 into a single coverage criterion allowing 25-hydroxyvitamin D serum testing no more than once every six months for specified patient groups.

    Chemotherapy was added to Note 1, letter N as a medication known to lower vitamin D levels.

    Note 1, letter DD and Note 2, letter N updated to read 'Chronic Kidney Disease and End Stage Renal Disease'.

    Added 'Granulomatous' to Note 1 and Note 2.

    1 per 6 moTesting frequency
    <20 ng/mLDeficiency threshold
    82306,82652,0038UProcedure codes
    >=3 moMinimum retest interval
    VDSCP CV ≤10%Assay certification

    Coverage Criteria for Vitamin D Testing

    Covered indications

    Covered when the specified conditions below are met

    25-hydroxyvitamin D (25OHD) coverage: 25-hydroxyvitamin D serum testing meets coverage criteria for individuals with an underlying disease/condition specifically associated with vitamin D deficiency or decreased bone density, for individuals suspected of hypervitaminosis of vitamin D, or for individuals with vitamin D deficiency.testing limited to no more than one test every six months

    Refer to Note 1 for list of qualifying conditions (see Note 1, letters A–FF).

    D2/D3 fraction testing: Testing for D2 and D3 fractions as part of the total 25-hydroxyvitamin D analysis meets coverage criteria.

    Included as part of total 25(OH)D analysis.

    1,25-dihydroxyvitamin D coverage: Serum 1,25-dihydroxyvitamin D testing meets coverage criteria for the evaluation or treatment of conditions associated with defects in vitamin D metabolism.

    Refer to Note 2 for qualifying indications (disorders of calcium metabolism, renal disease, granulomatous disorders, etc.).

    Indications for targeted testing / when covered

    Covered when testing is ordered for patients with risk factors or clinical conditions associated with potential vitamin D deficiency, as supported by specialty guidance.

    Primary covered indications: Patients with osteoporosis or low bone mineral density; patients with conditions causing malabsorption (e.g., celiac disease, inflammatory bowel disease, pancreatic insufficiency); patients undergoing bariatric surgery (preoperative and postoperative assessments); symptomatic vitamin D deficiency (for example, hypocalcemia or bone disease); patients with recurrent low‑impact fractures or other bone disease where vitamin D status will change management.

    References: AACE/ACE, ROS, AAP, and bariatric surgery society guidance.

    Not routinely covered / screening discouraged

    Testing is generally not supported for routine screening in asymptomatic general population groups.

    Populations for whom routine screening is discouraged: Asymptomatic adults (including across adult age groups and during pregnancy), healthy children without conditions associated with reduced bone mass, individuals without risk factors, and population‑based screening (including adults with obesity or dark complexion) — routine 25(OH)D screening is not recommended.

    Guideline sources (Endocrine Society, USPSTF, AAP, Manchester University NHS Trust) advise against population screening or find evidence insufficient.

    Retesting and monitoring criteria

    Retesting is appropriate only when clinically indicated and not earlier than recommended intervals.

    Retesting rules: Do not retest within 3 months of initiating vitamin D replacement or after a large loading dose; many guidelines recommend retesting no earlier than 3 months and preferably not within 6 months after initial testing or treatment. Avoid routine annual testing when levels are normal and risk factors are unchanged.>= 3 months (preferably >= 6 months)

    RACGP and Manchester University NHS Trust guidance: retest no earlier than 3 months and preferably not within 6 months; retesting within 4 weeks after a large loading dose may give misleading results.

    Combined CC (previously CC1 and CC3)

    Covered when ALL of the following are met

    Universal six-month testing frequency: For individuals with an underlying disease or condition specifically associated with vitamin D deficiency or decreased bone density, for individuals suspected of hypervitaminosis of vitamin D, or for individuals with vitamin D deficiency, 25-hydroxyvitamin D serum testing (no more than one test every six months) MEETS COVERAGE CRITERIA.once per 6 months

    See Note 1 and Note 2 for qualifying conditions; Note 1 letter N now explicitly includes chemotherapy as a medication known to lower vitamin D; Note DD and Note 2 N updated to 'Chronic Kidney Disease and End Stage Renal Disease'.

    Measurement of serum vitamin D is guided by clinical indications. Serum 25-hydroxyvitamin D (25OHD) testing is the recommended analyte for assessing vitamin D status and is covered when ordered for individuals with conditions specifically associated with vitamin D deficiency or decreased bone density, for suspected hypervitaminosis D, or for known vitamin D deficiency. The policy explicitly states that measurement of serum 1,25-dihydroxyvitamin D to screen for deficiency and routine screening of asymptomatic individuals do not meet coverage criteria.

    Routine population screening of asymptomatic individuals is discouraged. Multiple guideline sources cited in the policy — including the Endocrine Society and the American Academy of Pediatrics — recommend against routine 25(OH)D testing in the general adult population, during pregnancy, and in otherwise healthy children without risk factors. Testing should be targeted to patients with clinical indications or risk factors described in the policy notes rather than performed as population screening.

    The policy includes frequency limitations that operationally exclude repeat testing more often than every six months for covered indications. Retesting intervals are intended to allow sufficient time for serum concentrations to change after intervention; therefore, repeat 25‑hydroxyvitamin D testing performed more frequently than once every six months would not meet the revised coverage criterion except where otherwise noted in the qualifying conditions.

    The policy delineates the appropriate role of 1,25-dihydroxyvitamin D testing: it is covered for evaluation or management of conditions associated with defects in vitamin D metabolism but is not appropriate for routine screening to assess vitamin D status. For routine assessment of vitamin D status, 25-hydroxyvitamin D is the recommended and more stable analyte.

    Repeat testing guidance emphasizes clinical timing: do not retest within 3 months of initiating vitamin D replacement (including after a large loading dose), because early retesting may not reflect the true response to supplementation and can give misleading results. Many guidelines advise waiting up to six months before reassessment when monitoring therapy.

    Requests for 25-hydroxyvitamin D testing that occur more frequently than the policy limit of one test every six months for the covered indications are outside the updated coverage criteria and may be considered not medically necessary or subject to utilization review.

    Covered Indications and Qualifying Conditions

    inv-39: Individuals with diseases/conditions specifically associated with vitamin D deficiency or decreased bone density; suspected hypervitaminosis D; individuals with vitamin D deficiency; evaluation/treatment of defects in vitamin D metabolism.

    Underlying diseases/conditions list (refer to Note 1): Individuals with diseases/conditions specifically associated with vitamin D deficiency or decreased bone density (Note 1 includes: biliary cirrhosis; blind loop syndrome; celiac disease; coronary artery disease when considering chronic vitamin D therapy; dermatomyositis; eating disorders; bariatric surgery patients; disorders of calcium metabolism; hyperparathyroidism/hypoparathyroidism; hyperalimentation; inflammatory bowel disease; intestinal malabsorption; liver cirrhosis; long term use of anticonvulsants, glucocorticoids, chemotherapy and other medications known to lower vitamin D; malnutrition; myositis/myopathy; neoplastic hematologic disorders; osteogenesis imperfecta; osteomalacia; osteopetrosis; osteoporosis; pancreatic steatorrhea; tuberculosis; psoriasis; regional enteritis; renal/urinary calculus; rickets; sarcoidosis; Chronic Kidney Disease and End Stage Renal Disease; systemic lupus erythematosus; granulomatous disorders.

    See full Note 1 in policy for alphabetical list (A–FF).

    Conditions for 1,25-dihydroxyvitamin D testing (refer to Note 2): Individuals evaluated for conditions associated with defects in vitamin D metabolism (Note 2 includes: disorders of calcium metabolism; familial hypophosphatemia; Fanconi syndrome; hyperparathyroidism/hypoparathyroidism; hyperalimentation; neonatal hypocalcemia; osteogenesis imperfecta; osteomalacia; osteopetrosis; tuberculosis; renal/urinary calculus; rickets; sarcoidosis; Chronic Kidney Disease and End Stage Renal Disease; granulomatous disorders).

    Testing Frequency Limits

    inv-42: 25-hydroxyvitamin D — No more than one test
    Frequency limitNo more than one test
    Applicable test25-hydroxyvitamin D (25OHD) serum testing
    ContextApplies to individuals with an underlying disease/condition associated with vitamin D deficiency, suspected hypervitaminosis D, or documented vitamin D deficiency
    inv-43: 25‑hydroxyvitamin D (25(OH)D) — No repeat testing within 3 months of starting vitamin D replacement; preferably not within 6 months in many cases; avoid routine annual testing in some settings
    Minimum retest interval after starting replacementDo not retest within 3 months of beginning vitamin D replacement; many guidelines prefer not to retest within 6 months
    Routine annual testingAvoid routine annual testing when levels are normal and risk factors unchanged

    Procedure Codes and Thresholds

    Covered CPT Codes (25‑hydroxyvitamin D)CPT
    82306Vitamin D; 25 hydroxy, includes fraction(s), if performed
    Covered CPT Codes (1,25‑dihydroxyvitamin D)CPT
    82652Vitamin D; 1, 25 dihydroxy, includes fraction(s), if performed
    Proprietary / HCPCS‑like codemixed
    0038UVitamin D, 25 hydroxy D2 and D3, by LC-MS/MS, serum microsample, quantitative Proprietary test: Sensieva ™ Droplet 25OH Vitamin D2/D3 Microvolume LC/MS Assay
    Covered CPT/HCPCS CodesCPTCovered
    82306Vitamin D; 25 hydroxy, includes fraction(s), if performed
    82652Vitamin D; 1, 25 dihydroxy, includes fraction(s), if performed
    0038UVitamin D, 25 hydroxy D2 and D3, by LC-MS/MS, serum microsample, quantitative Proprietary test: Sensieva ™ Droplet 25OH Vitamin D2/D3 Microvolume LC/MS Assay
    inv-16: Vitamin D deficiency threshold — < 20 ng/mL
    Deficiency thresholdSerum 25OHD < 20 ng/mL
    IOM recommended rangeMaintain serum 25OHD between 20 and 40 ng/mL (50–100 nmol/L)
    Alternative expert targetSome experts favor 30–50 ng/mL as optimal for certain patients
    inv-17: Recommended serum targets or thresholds — ROS/AACE thresholds and guidance
    ROS thresholds (nmol/L)<25 nmol/L = deficient; 25–50 nmol/L = possibly inadequate; >50 nmol/L = sufficient
    AACE threshold for osteoporosis patients

    Provider Actions, Documentation, and Billing Guidance

    Billing Rule

    Procedure codes and review

    Procedure codes for vitamin D testing are listed below. Use these codes on claims and expect standard coding review for medical necessity and frequency limits.

    • 82306 — Vitamin D; 25 hydroxy, includes fraction(s), if performed
    • 82652 — Vitamin D; 1,25 dihydroxy, includes fraction(s), if performed
    • 0038U — Vitamin D, 25 hydroxy D2 and D3, by LC-MS/MS, serum microsample, quantitative (Proprietary test: Sensieva™ Droplet 25OH Vitamin D2/D3 Microvolume LC/MS Assay)
    Denial Risk

    Required coverage determination for vitamin D assay codes

    Ordering Requirements

    Note

    Order tests based on policy clinical indications

    Order vitamin D tests only when the clinical indications listed in the policy are present (underlying diseases, disorders of vitamin D metabolism, medications affecting vitamin D).

    • See Note 1 and Note 2 for full lists of qualifying conditions and medications.
    Note

    Order tests for listed clinical conditions (osteoporosis, malabsorption, bariatric patients, symptomatic deficiency)

    Place orders for testing when clinically indicated by the conditions listed (for example, osteoporosis/low BMD, malabsorption, pre/post bariatric surgery, or symptomatic deficiency).

    • ROS and AACE guidance cited for osteoporosis‑related testing recommendations.
    Billing Rule

    Use referenced codes and document indication; follow frequency limits

    Services Not Covered

    The policy does not support routine population screening for vitamin D deficiency in asymptomatic individuals; it also specifies that measurement of serum 1,25-dihydroxyvitamin D for general screening purposes does not meet coverage criteria. Orders for vitamin D testing should be limited to the clinical indications and qualifying conditions listed in the policy notes.

    Routine screening of asymptomatic groups — including the general adult population, healthy children without risk factors, and routine pregnancy screening — is not routinely supported and therefore not covered. Guideline statements cited in the policy (e.g., Endocrine Society, USPSTF, AAP) advise against population‑based screening and recommend targeted measurement only for individuals with relevant clinical indications.

    Repeat 25-hydroxyvitamin D testing more frequently than once every six months for covered indications is not supported by the revised coverage criteria. The policy combines prior criteria to enforce a universal six‑month frequency limit for 25‑OH vitamin D testing in the specified patient groups.

    Definitions and Test Names

    inv-33: 25(OH)D / 25OHD — 25-Hydroxyvitamin D, the predominant and most stable circulating form used to assess vitamin D status.
    Definition25-Hydroxyvitamin D (25OHD) — the predominant and most stable circulating form used to assess vitamin D status
    SynonymsAlso referred to as 25(OH)D or calcidiol
    Clinical rolePreferred laboratory analyte for evaluating vitamin D status due to longer half-life (~15 days)
    inv-34: 1,25-dihydroxyvitamin D — The metabolically active form of vitamin D (calcitriol) with a short circulating half-life, used for evaluation of defects in vitamin D metabolism.
    Definition1,25-dihydroxyvitamin D (calcitriol) — the metabolically active form of vitamin D with a short circulating half-life (~15 hours)
    Clinical use

    Background and Rationale

    For clinical context, 25-hydroxyvitamin D (25OHD) is the predominant and most stable circulating form used to assess vitamin D status and is therefore the primary analyte for testing. By contrast, 1,25-dihydroxyvitamin D is the active metabolite with a much shorter circulating half-life and is reserved for evaluation of specific metabolic defects rather than routine status screening.

    Policy Summary
    Payermedical mutual - ohio
    PolicyVitamin D Testing
    Policy CodePolicy AHS - G2005
    Change TypeCoverage criteria revisedmaterial changes
    Effective DateJun 1, 2026
    Last ReviewDec 3, 2025
    Next Review DateDec 3, 2025
    Key ActionWhen ordering 25-hydroxyvitamin D, document a qualifying clinical indication and limit testing to no more than one test every six months for covered indications.
    SourceLink
    On This Page
    Coverage Criteria for Vitamin D TestingCovered Indications and Qualifying ConditionsTesting Frequency LimitsProcedure Codes and ThresholdsProvider Actions, Documentation, and Billing GuidanceOrdering RequirementsServices Not CoveredDefinitions and Test NamesBackground and Rationale

    Refer to Note 2 for complete list.

    inv-40: Assessment of vitamin D status in patients with or at risk for bone disease (osteoporosis, low BMD), symptomatic deficiency, malabsorption, preoperative and postoperative evaluation for bariatric surgery patients.

    Assessment in bone disease and related conditions: Assessment of vitamin D status is covered for patients with or at risk for bone disease (including osteoporosis and low BMD), symptomatic deficiency (e.g., hypocalcemia, bone disease), malabsorption syndromes, and for preoperative and postoperative evaluation in bariatric surgery patients.

    Guidance sources: AACE/ACE, ROS, and bariatric surgery society recommendations.

    inv-41: Individuals with an underlying disease or condition specifically associated with vitamin D deficiency or decreased bone density; individuals suspected of hypervitaminosis of vitamin D; individuals with vitamin D deficiency. (chemotherapy added as medication known to lower vitamin D)

    Expanded covered individuals and medication considerations: Individuals with an underlying disease or condition specifically associated with vitamin D deficiency or decreased bone density; individuals suspected of hypervitaminosis of vitamin D; and individuals with vitamin D deficiency. Note 1 and Note 2 provide expanded lists of qualifying conditions and include granulomatous disorders and chronic kidney disease/ESRD; Note 1 letter N now explicitly includes chemotherapy as a medication known to lower vitamin D levels.

    See Note 1 and Note 2 for full qualifying condition lists.

    Empiric treatment guidanceHigh-risk asymptomatic individuals may be treated without prior measurement in some settings (Manchester NHS guidance)
    inv-44: 25-hydroxyvitamin D serum testing — no more than one test every six months
    Universal frequency limitNo more than one 25-hydroxyvitamin D serum test every six months
    Covered populationsIndividuals with conditions associated with vitamin D deficiency, suspected hypervitaminosis D, or documented vitamin D deficiency
    Policy changeRevision combined prior coverage criteria to operationally enforce once-per-six-months testing
    Maintain serum 25(OH)D ≥30 ng/mL (preferable 30–50 ng/mL)
    IOM recommended range25OHD 20–40 ng/mL cited by IOM as acceptable range
    inv-18: Testing frequency — no more than once every six months
    Maximum testing frequencyNo more than once every six months for covered indications
    Minimum retest after replacementDo not retest within 3 months of starting vitamin D replacement; retesting preferably after 6 months in many cases
    Avoid routine repeat testingAvoid routine annual testing when levels are normal and risk factors unchanged

    Testing for 25-hydroxyvitamin D (and D2/D3 fractions) is covered only when the policy's clinical coverage criteria are met. The policy incorporates a universal frequency limit: no more than one 25-hydroxyvitamin D test every six months for covered indications.

    • Covered assay codes: 82306 and 0038U for 25‑hydroxyvitamin D (including D2/D3 fractions).
    • Frequency limit: ≤1 test per 6 months for covered indications.
    • Requests not meeting clinical criteria or exceeding frequency may be denied or returned for additional documentation.
    Denial Risk

    1,25-dihydroxyvitamin D screening excluded

    Measurement of serum 1,25-dihydroxyvitamin D is NOT appropriate for screening for vitamin D deficiency and does not meet coverage criteria when used for that purpose. 1,25-dihydroxyvitamin D testing is covered only for evaluation or treatment of conditions associated with defects in vitamin D metabolism as listed in Note 2.

    • Do not order 82652 for routine screening of vitamin D deficiency.
    • 82652 may be covered when used for the specific metabolic indications enumerated in Note 2.
    Denial Risk

    Early repeat testing risk

    Retesting too soon after an intervention or supplementation is discouraged. Evidence and guideline recommendations advise against early repeat testing because serum levels may not have had time to respond.

    • Avoid repeat 25‑OH vitamin D testing within 3 months of starting supplementation; many recommendations prefer waiting 3–6 months.
    • Retesting within 4 weeks of a large loading dose can give false evidence of over-repletion.
    • Early repeat testing may be denied if performed before the policy frequency limit or guideline-recommended interval.
    Documentation Required

    Clinical indication documentation

    Document the clinical indication when ordering 25‑hydroxyvitamin D testing. Orders should align with the policy's listed indications for testing (Note 1 for 25‑OH testing and Note 2 for 1,25‑OH testing). Routine screening in asymptomatic individuals is excluded.

    • State the specific indication on the order (e.g., 'malabsorption', 'post‑bariatric surgery', 'long‑term glucocorticoid therapy').
    • Do not order for general screening in asymptomatic patients without a listed indication.
    Documentation Required

    Required clinical documentation

    When submitting requests for coverage or prior authorization (if applicable), include pertinent biochemical data and prior vitamin D measurements to support medical necessity.

    • Provide recent serum calcium and phosphorus levels.
    • Include alkaline phosphatase and parathyroid hormone (PTH) results when available.
    • Attach previous 25‑OH vitamin D test results if monitoring response to therapy (noting date and value).
    Billing Rule

    Ordering documentation

    Orderers must document the indication on the lab order and adhere to the policy frequency limit of no more than one 25‑hydroxyvitamin D test every six months for covered indications.

    • Include the clinical reason on the requisition when ordering (e.g., monitoring supplementation for documented deficiency, evaluation of disorders listed in Note 1).
    • If monitoring therapy, indicate prior result date and value; testing more frequently than every 6 months may be outside coverage.
    Note

    Therapeutic monitoring implication

    Measurement of 25‑hydroxyvitamin D may be used for therapeutic monitoring in certain populations (for example, individuals on chronic glucocorticoid therapy >3 months, patients with malabsorption, or those receiving high‑dose supplementation), provided monitoring adheres to the policy frequency limit.

    • Document that testing is being used to guide supplementation or therapeutic decisions (e.g., dose adjustment).
    • Therapeutic monitoring should respect the policy limit of one test per six months except where clinical justification for earlier testing is documented and medically necessary.
    Note

    Empiric treatment vs testing

    For certain high‑risk, asymptomatic individuals, empiric vitamin D supplementation without prior laboratory measurement is acceptable and recommended by some guidelines; avoid unnecessary testing in these groups.

    • Treat asymptomatic high‑risk adults (e.g., those with risk factors for deficiency) empirically with supplementation rather than routine testing when appropriate.
    • Reserve testing for individuals with symptoms, complications, or when results will change management.
    Note

    Providers: ensure all required elements (indication, relevant labs, prior results, and adherence to frequency limits) are included with orders to avoid claim denials or requests for additional information.

    When ordering, use the referenced CPT/HCPCS codes and document the clinical indication consistent with the policy; adhere to the stated frequency limits to avoid denial.

    • Referenced codes include 82306, 82652, and 0038U; frequency limit: no more than one test every six months for covered indications.
    Used to evaluate defects in vitamin D metabolism rather than routine status assessment
    Not for screeningMeasurement for screening vitamin D deficiency is not recommended and does not meet coverage criteria
    inv-35: 25(OH)D — Serum 25‑hydroxyvitamin D — the recommended laboratory analyte for assessing vitamin D status; CPT code 82306 corresponds to this test.
    AnalyteSerum 25‑hydroxyvitamin D (25(OH)D) — recommended laboratory analyte for assessing vitamin D status
    CPT codeCPT 82306 corresponds to Vitamin D; 25 hydroxy (includes fractions if performed)
    Preferred test25(OH)D preferred over 1,25-dihydroxyvitamin D for routine status assessment due to stability
    inv-36: 1,25‑dihydroxyvitamin D — Active metabolite measured by CPT 82652; guidelines focus on 25(OH)D and generally do not recommend routine 1,25‑dihydroxyvitamin D testing.
    Analyte1,25‑dihydroxyvitamin D — active metabolite measured for defects in vitamin D metabolism
    CPT codeCPT 82652 corresponds to Vitamin D; 1,25 dihydroxy
    Routine useGuidelines and policy generally do not recommend routine 1,25‑dihydroxyvitamin D testing for status assessment and exclude its use for screening
    inv-37: Vitamin D; 25 hydroxy (CPT 82306) — 25-hydroxyvitamin D
    Test nameVitamin D; 25 hydroxy
    CPT code82306
    NoteIncludes fraction(s) if performed
    inv-38: Vitamin D; 1,25 dihydroxy (CPT 82652) — 1,25-dihydroxyvitamin D
    Test nameVitamin D; 1,25 dihydroxy
    CPT code82652
    NoteIncludes fraction(s) if performed